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Abstract
Heme oxygenase-1 (HO-1), a cytoprotective, pro-angiogenic and anti-inflammatory enzyme, is strongly induced in injured
tissues. Our aim was to clarify its role in cutaneous wound healing. In wild type mice, maximal expression of HO-1 in the skin
was observed on the 2nd and 3rd days after wounding. Inhibition of HO-1 by tin protoporphyrin-IX resulted in retardation of
wound closure. Healing was also delayed in HO-1 deficient mice, where lack of HO-1 could lead to complete suppression of
reepithelialization and to formation of extensive skin lesions, accompanied by impaired neovascularization. Experiments
performed in transgenic mice bearing HO-1 under control of keratin 14 promoter showed that increased level of HO-1 in
keratinocytes is enough to improve the neovascularization and hasten the closure of wounds. Importantly, induction of HO-
1 in wounded skin was relatively weak and delayed in diabetic (db/db) mice, in which also angiogenesis and wound closure
were impaired. In such animals local delivery of HO-1 transgene using adenoviral vectors accelerated the wound healing
and increased the vascularization. In summary, induction of HO-1 is necessary for efficient wound closure and
neovascularization. Impaired wound healing in diabetic mice may be associated with delayed HO-1 upregulation and can be
improved by HO-1 gene transfer.
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Introduction
The repair of wound is a complex process engaging activity of
various cell types, tightly orchestrated by specific cytokines. The
molecular and cellular machinery, which is switched on in
response to destructive stimuli, is very similar in case of burn,
cutaneous wounds, myocardial infarction, spinal-cord damage,
and visceral injuries [1]. Noteworthy, chronic nonhealing wounds,
leading very often to ulceration, necrosis and amputation, are one
of the severe consequences of diabetes, which result in significant
morbidity. Especially in this case, the new avenues for therapeutic
approaches of deep skin injuries are urgently needed.
In mammals, skin wound healing occurs in three overlapping
phases: inflammation, granulation tissue formation and remodel-
ing [2]. Briefly, the injury causes immediate blood vessel
constriction and activation of coagulation cascade. When the
blood clot is formed, neutrophils and monocytes enter the wound
site. Then, keratinocytes and fibroblasts are stimulated to
proliferate and migrate over the provisional matrix, so the
granulation tissue formation begins. During the final phase of
wound healing the granulation tissue is replaced with an acellular
scar, when myofibroblastic and vascular cells in the wound
undergo apoptosis [3].
Vascularization of wound, achieved both by angiogenesis
(formation of blood vessels from preexisting ones) and vasculo-
genesis (formation of blood vessels from endothelial progenitor
cells), is necessary for quick and effective tissue repair. It has been
shown that endostatin, an angiogenesis inhibitor, delayed wound
healing through attenuation of granulation tissue formation and
vascularization in mice [4], and impaired maturation of blood
vessels during the restoration of skin integrity [5], although
reepithelialization of wound was not affected [4,5]. Moreover,
neutralizing antibodies against vascular endothelial growth factor
(VEGF), the major angiogenic and vasculogenic mediator,
inhibited formation of granulation tissue and decreased number
of blood vessels [6], whereas VEGF overexpression by ex vivo
expanded keratinocyte cultures promoted matrix formation,
angiogenesis, and healing in porcine full-thickness wounds [7].
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Also diabetic wound healing was accelerated in response to VEGF
via increased angiogenesis and recruiting bone marrow-derived
cells [8]. Finally, transplantation of endothelial progenitor cells
(EPCs) improved dermal wound healing, showing the potency of
blood vessel-directed cell therapy [9].
One of the important molecular mediators of new blood vessel
formation is heme oxygenase-1 (HO-1). This cytoprotective
enzyme, strongly induced by pro-oxidants and inflammatory
agents, degrades heme to three compounds: CO, free iron and
biliverdin, which is subsequently reduced to bilirubin by biliverdin
reductase [10]. Previous studies have revealed the significance of
HO-1 in regulation of synthesis and activity of VEGF [11–14] and
its role in angiogenesis [15,16]. Recently we have indicated an
importance of HO-1 in stromal cell derived factor-1 (SDF-1)-
dependent neovascularization, showing delayed wound closure
and poor vascularity of wounded skin in 3-month old HO-1
knockout mice [17].
It has been shown that HO-1 is rapidly induced in the wounded
tissues [18,19]. Keeping in mind its pro-angiogenic, anti-
inflammatory and cytoprotective properties, as well as its influence
on cell proliferation and migration [20], one can suppose that
expression of HO-1 may play a role in the process of wound
healing. The aim of our study was to verify this hypothesis. We
evidenced the significance of HO-1 in skin repair, and demon-
strated that delayed HO-1 induction may contribute to the
impairment of wound healing in diabetes. Accordingly, we showed
that HO-1 gene transfer may facilitate wound closure and
neovascularization in diabetic mice.
Results
Effect of SnPPIX on wound closure
First experiments were performed in vitro on human keratinocyte
cell line HaCaT, using a scratch assay model. Incubation of cells
with tin protoporphyrin (SnPPIX, a competitive inhibitor of heme
oxygenases, 10 mmol/mL) significantly slowed down the closure of
gap created on the confluent cell monolayer (Fig. 1A,B). Most
likely this resulted from reduction of keratinocyte migration, not
proliferation, as all experiments were performed in the presence of
10 mM hydroxyurea, a cell cycle blocker.
Then we investigated the wound healing process in vivo, in 3-
month old C57BL wild type mice. Two circular wounds (4 mm in
diameter) on the dorsum of each animal were created using biopsy
punch. In the first step we checked the effect of wounding on HO-
1 expression. By means of western-blotting we investigated the
level of HO-1 protein in the tissue lysates prepared from healthy
and wounded skins. As shown in Fig. 2A, expression of HO-1 in
the healthy tissue was relatively low. Upon injury it was rapidly
Figure 1. Effect of SnPPIX (10 mmol/L) on time of gap closure by HaCaT cells cultured in vitro in the presence of hydroxyurea
(10 mmol/L). Scratch assay. A – Quantitative data. Each point represents mean6SD of 3 experiments done in duplicates. * P,0.05 in comparison to
control. B – representative pictures. Scale bar = 200 mm.
doi:10.1371/journal.pone.0005803.g001
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Figure 2. A - Expression of HO-1 protein in healthy and wounded skin. H - healthy skin, PC - positive control (HaCaT cells stimulated with
10 mmol/L of hemin for 24 h). Western blot analysis. Tubulin was used as a housekeeping gene to control the protein loading. One of 3 similar blots.
B - Effect of SnPPIX (45 mmol/kg of body weight) injected subcutaneously (once a day for 10 days) on wound closure in C57BL mice. C – Effect of
SnPPIX (45 mmol/kg of body weight), injected intraperitoneally (once a day for 10 days) on wound closure in C57BL mice. Each bar represents
mean+SD; N= 10 animals per group. * P,0.05, ** P,0.01 in comparison to control, vehicle injected animals. D – representative pictures taken
immediately after wounding, and on the 3rd and 7th days. Scale bar = 1 mm.
doi:10.1371/journal.pone.0005803.g002
HO-1 Accelerates Wound Healing
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5803
upregulated and remained very high on day 1st, 2nd, and 3rd, then
gradually decreased.
In the second step we examined the effect of SnPPIX on wound
healing. To this end, immediately after wounding, mice were divided
into four groups and injected every day for 10 consecutive days
either intraperitoneally (i.p.) or subcutaneously (s.c.) with SnPPIX or
with vehicle. The animals were photographed every day to measure
the wound surface. Analysis of images revealed that mice treated s.c.
with SnPPIX showed a delayed wound closure compared to mice
injected with the vehicle, which was evident throughout the whole
process of healing, beginning from day 1st (Fig. 2B,D). The first fully
closed wounds in control mice were found on the 7th day after
wounding, whereas in SnPPIX-treated group they appeared earliest
on day 8th. In case of i.p. injected animals, the delay did not become
apparent until the 3rd day after injury, which might be associated
with less effective penetration of the inhibitor to the wounded tissue
than after local injection. However, similarly as in the s.c. treated
individuals, the delayed wound healing was clearly visible
(Fig. 2C,D). Again, in the vehicle injected mice the fully closed
wounds appeared first on the 7th day after wounding, whereas in the
SnPPIX treated group on the 8th day. Thus, s.c. and i.p. injections of
SnPPIX result in impaired wound closure in mice, which may
suggest that HO-1 plays a role in the process of wound healing.
Effect of HO-1 deficiency on wound healing
SnPPIX is commonly used to suppress HO-1 activity in cell culture
and animal experiments. However, it exerts also a variety of non-
specific, HO-1 independent effects [21,22]. Therefore, to confirm the
importance of HO-1, we investigated the wound healing process in
C57BLxFVB mice of normal level of HO-1 (HO-1+/+) and mice
lacking one (HO-1+/2) or both (HO-12/2) HO-1 alleles.
As we have already noticed in the earlier paper [17], lack of
HO-1 was associated with significantly delayed wound closure in
the 3-month old HO-12/2 mice compared to the wild type
animals of the same age (Fig. 3A). Noteworthy, the most
pronounced differences were observed during the first phases of
healing, between 1st and 6th day after injury, at the time of the
strongest induction of HO-1 in the wounded skin (Fig. 2A). The
rate of wound healing in the heterezygous (HO-1+/2) animals, was
similar to that in HO-1+/+ mice (Fig. 3A).
Effect of HO-1 deficiency on wound healing in the older, 6-month
old animals, was remarkable. Time required for wound closure in the
wild type mice did not differ significantly compared to the younger
ones. However, lack of even one functional HO-1 allele resulted in a
potent delay in wound healing (Fig. 3B). In some individuals (both
HO-1+/2 and HO-12/2) wounds did not cure at all and their surface
increased with time forming large unhealing lesions (Fig. 3C). Such
animals had to be subjected to euthanasia before the planned end of
experiment. Immunohistochemical staining of CD31-positive endo-
thelial cells, carried out on the day 17th after injury, demonstrated
that number of blood vessels was lower in nonhealing than in healing
skins of HO-1 deficient individuals (9.7661.64 versus 11.8461.66 of
vessels per surface unit, P=0.035). Necrotic areas were also visible
within the wounds. However, the mechanism behind reduced
vascularization is not clear, as we did not observe any significant
differences in concentration of VEGF, SDF-1 or tumor necrosis
factor-a (TNFa) in the tissue lysates prepared from the healing and
nonhealing wounds (data not shown).
Effect of SnPPIX and HO-1 deficiency on production of
inflammatory mediators
Since restoration of tissue integrity and function is strongly
dependent on inflammation, we compared the influence of
subcutaneous injection of SnPPIX and HO-1 deficiency on a
profile of cytokines in the blood serum of mice on the 3rd day post-
wounding, using a protein macroarrays (RayBiotech).
We found that SnPPIX strongly decreased concentrations of
many inflammatory mediators in the blood of wounded mice
(Tab. 1). Some of those effects were possibly HO-1 dependent, as
similar downregulations were observed in HO-1+/2 and HO-12/2
animals. Namely, the coherent results were obtained for soluble
CD40 antigen (sCD40), granulocyte-macrophage colony stimulat-
ing factor (GM-CSF), interferon-c (IFNc), interleukin-2 (IL-2), IL-
17, and KC (murine ortholog of IL-8). One can suppose that
reduction of some of these mediators may potentially contribute to
impairment of wound healing in response to pharmacological or
genetic inhibition of HO-1.
In case of VEGF we observed decreased concentration in HO-
1+/2 and HO-12/2 mice, but not in animals treated with SnPPIX,
where inhibition of HO-1 might be too weak. Tendency for reduced
production of VEGF in HO-1 deficient mice was confirmed by
ELISA performed in cell lysates prepared from the wounded skins 3
days after injury, where VEGF concentration in comparison to HO-
1+/+ animals was decreased to 62.4641.0% (P=0.075) and to
74.9616.2% (P=0.071) for HO-1+/2 and HO-12/2, respectively.
Interestingly, we also observed significant decrease in amount of
SDF-1, which reached 44.6621.9% (P=0.005) in HO-1+/2 and
35.6618.0% (P=0.002) in HO-12/2mice, in comparison to values
measured in wild type individuals.
Finally, several effects of SnPPIX were clearly HO-1 indepen-
dent, being opposite to the results of HO-1 deficiency, as
demonstrated for soluble CD30T antigen, chemokine CXCL-10,
IL-10, IL-12 or IL-13. Keeping in mind that both pharmacological
and genetic HO-1 inhibition impairs wound healing, we suppose
that those mediators are not involved in the process studied.
Effect of skin-specific HO-1 overexpression on wound
healing
We decided to investigate whether local overexpression of HO-
1 may facilitate wound healing. Therefore, we created the
transgenic mice (HO-1Tg) bearing human HO-1 gene under
control of the human keratin 14 promoter to overexpress HO-1
specifically in keratinocytes, in the epidermal layer of the skin.
Analysis of the primary keratinocytes isolated from such mice and
cultured in vitro evidenced the upregulated HO-1 expression both
at mRNA level, as shown by RT-PCR (Fig. 4A), and at protein
level, as visualized by immunohistochemical staining (Fig. 4B) and
quantified by ELISA (Fig. 4C). Such overexpression was not
observed in other cell types analyzed (data not shown).
Interestingly, the augmented expression of HO-1 accelerated
the closure of scratch in a monolayer of primary transgenic
keratinocytes, as demonstrated by in vitro wound healing assay
(Fig. 5A). This indicates that HO-1 improves migration of
keratinocytes. Cells isolated from transgenic mice displayed also
a tendency to increased proliferation, however this did not reach
statistical significance (Fig. 5B). Finally, HO-1 overexpression
improved viability of cells kept for 24 h under hypoxic conditions
(1% O2) (Fig. 5C), and slightly increased production of VEGF
induced by hypoxia (Fig. 5D).
Wound healing experiments performed in vivo on HO-1Tg mice
showed that increased expression of HO-1 in keratinocytes is
enough to accelerate significantly the wound closure throughout
the whole process of healing, starting from day 1st (Fig. 6A).
Effect of HO-1 expression on vascularization of wounds
Vascularization of wounds was assessed in 3-month old mice of
different genotypes by immunohistochemical staining of endothe-
lial cells using anti-CD31 antibodies. It turned out that density of
HO-1 Accelerates Wound Healing
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blood vessels, measured three days after injury, reflected very well
the rate of wound healing. Vascularization was the same in the
HO-1+/+ and HO-1+/2 mice, whereas in HO-12/2 animals the
number of vessels was significantly lower. Accordingly, overex-
pression of HO-1 in the HO-1Tg mice was associated with strongly
increased angiogenesis (Fig. 6B).
Figure 3. Closure of cuteneous wounds in the HO-1+/+ (WT), HO-1+/2 (HT), or HO-12/2 (KO) C57BLxFVB mice. A – 3-month old animals.
B – 6-month old animals. Each point represents individual animal (N = 4–5), lines connect the median values. Crossed points represent animals
subjected to euthanasia. * P,0.05, ** P,0.01 in comparison to WT. C – representative pictures showing the wounds in 6-month old animals
immediately after wounding and on day 10th. Scale bar = 5 mm.
doi:10.1371/journal.pone.0005803.g003
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Expression of HO-1 during wound healing in diabetic
mice
Wound healing is impaired in diabetes. We wanted to examine
the expression of HO-1 in diabetic wounds. To this end, we
performed experiments in hyperglycemic db/db mice, which are a
model of human type 2 diabetes. As expected, db/db mice
exhibited delayed wound closure compared to wild type animals
(Fig. 7A). This retardation was evident throughout the whole
process of healing, starting form the 1st day. Wound closure in
diabetic animals was completed 15 days after wounding, 5 days
later than in their wild type counterparts.
Delayed healing was associated with significantly decreased
tissue vascularization. In healthy skins, numbers of vessels in the
wild type and db/db mice were similar, as revealed by CD31
staining. In both cases tissue injury induced angiogenesis, and
vessel density reached the highest level on the 3rd day. However,
this increase was much weaker in diabetic mice compared to wild
type animals (Fig. 7B,C). When wound healing process was
ending, nonfunctional capillaries underwent regression and the
number of vessels decreased in both groups.
Western blot analyses showed that expression of HO-1 was
upregulated after injury both in wild type and db/db mice.
However the time course of this process was different. In the wild
type animals HO-1 expression reached the highest level during
first three days post-wounding, whereas in db/db mice the
maximal HO-1 induction was postponed, with the highest level of
expression on day 8 (Fig. 7D). Thus, during the first phases of
response to injury, expression of HO-1 was weaker in diabetic
than in wild type animals. Such impaired induction of HO-1 we
observed also after intradermal injection of hemin, a substrate and
potent inducer of HO-1 expression. In wild type animals local
injection of hemin resulted in a strong upregulation of HO-1
protein in the healthy skin. In contrast, the same treatment led to a
very weak response in the skin of db/db mice (Fig. 7E).
Effect of HO-1 gene transfer on wound healing in
diabetic mice
Because expression of HO-1 was disturbed in the wounds of
diabetic mice, we investigated whether transfer of HO-1 gene into
the injured tissue may improve the healing process. To address this
question, we produced adenoviral vectors harboring rat HO-1
cDNA (AdHO-1) or control GFP cDNA (AdGFP) under control of
CMV promoter. In vitro experiments evidenced that these carriers
provided high level of transgene expressions (data not shown).
Immediately after injury db/db mice were injected intrader-
mally at four sites around the wounds either with AdGFP or
AdHO-1 vectors (2.36107 IU per wound). This treatment did not
induce any noticeable side effects, as evidenced by unchanged level
of aspartate aminotransferase in the blood of animals (data not
shown). The presence of transduced cells in the skin was confirmed
by GFP expression on the 3rd day in the injured tissue (Fig. 8A).
We did not find GFP-positive cells in any other organ analyzed
(liver, kidney, lungs, spleen), which indicates that transgene
localized only near the site of injection. However, the level of
transgene expression was low and we were unable to detect the
differences in HO-1 protein concentration in tissue lysates
prepared from the wounded skin of AdHO-1 and AdGFP injected
animals on day 3 after injection (Fig. 8B). Importantly, RT-PCR
with primers specific for rat HO-1 evidenced transgene expression
at mRNA level already on day 1 and also on day 3 after injection
(Fig. 8C). This was fully confirmed by quantitative, real-time RT-
PCR (signal undetectable in AdGFP injected wounds; HO-1/EF2
Table 1. List of genes differently expressed in animals with pharmacologically or genetically inhibited HO-1, 3 days after
wounding.
Gene C57Bl WT+PBS C57Bl +SnPPIX C57BlxFVB WT C57BlxFVB HT C57BlxFVB KO
CD40 + 2 + 2 2
GM-CSF + 2 + 2 2
IFNc + 2 + 2 2
IL-2 + 2 + 2 2
IL-17 + 2 + 2 2
KC + 2 + 2 2
VEGF + + + 2 2
Lymphotactin + + + 2 2
CCL-24 + + + + 2
Leptin + + + + 2
CCL-27 + + 2 + +
CXCL-16 + + 2 + +
CXCL-13 + + 2 2 +
IL-3 + + 2 2 +
CD30T + 2 2 + +
CXCL-10 + 2 2 + +
IL-13 + 2 2 + +
IL-10 + 2 2 2 +
IL-12 p70 + 2 2 2 +
Presence of proteins in the serum of mice was analyzed using RayBiotech arrays followed by densitometric measurements. Data are shown as semiquantitative
estimations of signals: + indicates OD.0.1 of value measured for positive control.
doi:10.1371/journal.pone.0005803.t001
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ratio 0.01460.0097 P,0.0132 for AdHO-1 treated wounds on
day 1st). On the other hand, real-time RT-PCR with primers
recognizing both murine and rat HO-1, indicated the tendency for
increased expression of total HO-1 mRNA, but the differences
between AdGFP and AdHO-1 injected mice did not reach
statistical significance. Namely, HO-1 to EF2 reference gene ratio
was 0.05260.020 in AdGFP and 0.07160.031 in AdHO-1
(P = 0.056) on day 1 and 0.05460.026 in AdGFP and
0.06560.009 (P= 0.230) on day 3. Possibly, transgene expression
is masked by significant induction of endogenous enzyme in
response to injury, as the HO-1/EF2 ratio in healthy skin was
0.01360.012. It appears however, that local expression of HO-1
in the transduced cells can be upregulated. This supposition is
supported by measurement of HO-1 protein at later time points,
when expression of endogenous HO-1 is already diminished.
Thus, although we observed similar upregulation of HO-1
expression on the 3rd day post-wounding both in AdGFP and
AdHO-1 treated wounds, the higher HO-1 protein concentration
on 14th day was observed in AdHO-1 injected wounds (Fig. 8B).
Despite the low level of transgene expression, wound closure
analysis showed accelerated wound healing in AdHO-1 injected
mice, visible during the earlier phases of healing, between days 1
and 7 after injury (Fig. 9A). Moreover, improved wound healing
was accompanied by increased number of blood vessels within the
wounds, as shown by staining for CD31 (Fig. 9B,C). On the 3rd
day, much stronger vascularization was observed in AdHO-1
injected wounds than in AdGFP treated ones. The number of
capillaries decreased on 14th day post-wounding. Taken together,
HO-1 gene transfer may improve wound healing in db/db mice,
which is associated with increased blood vessel formation.
Discussion
HO-1 is a cytoprotective enzyme playing a role in regulation of
angiogenesis and in modulation of immune response [11–
17,23,24]. Its involvement in proper function of cardiovascular
system, efficient neovascularization of ischemic tissues or progres-
sion of tumors is relatively well known [24]. However, significance
of HO-1 in wound healing has not been established. Our study
demonstrates that: i) pharmacological or genetic inhibition of HO-
1 impairs healing of cutaneous wounds in mice; ii) induction of
HO-1 in response to injury is impaired in diabetic mice, in which
wound healing is delayed; iii) this delay may be partially reversed
by HO-1 overexpression, the effect associated with increased
vascularization of the wounded tissue.
Wounding leads to hemolysis and release of toxic free heme,
which is a potent inducer of HO-1 expression, and a physiologic
trigger to start inflammatory processes [25]. It has been suggested
that HO-1 could be involved in the control of wound healing and
might serve as a protective agent against oxidative and
Figure 4. HO-1 overexpression in murine keratinocytes. A – Expression of human HO-1 mRNA in the skin of HO-1+/+ and transgenic HO-1Tg
mice C57BL mice. Electrophoresis of RT-PCR products (2% agarose gel). EF2 was used as a housekeeping gene. One of 4 similar analyses. B –
Representative pictures of immunocytofluorescent staining for HO-1 in primary murine keratinocytes isolated from newborns and cultured in vitro.
Scale bar = 100 mm. C – Concentration of HO-1 in lysates of primary murine keratinocytes isolated from newborns and cultured in vitro. ELISA. Each
bar represents mean+SD of 6 measurements. *** P,0.001 in comparison to HO-1+/+.
doi:10.1371/journal.pone.0005803.g004
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inflammatory insults [18,25]. This suggestion has been supported
by observation that pharmacological induction of HO-1 was
associated with a significant acceleration of wound healing and
attenuation of the inflammatory response in injured corneal
epithelium [26]. Also a clinical analysis of sickle cell anemia
patients, which showed a connection between a higher HO-1
activity, reflected by serum bilirubin, and protection against leg
ulcers might suggest a role of HO-1 in wound healing [27].
In our model of excisional wound, the rapid upregulation of
HO-1 mRNA and protein was observed upon injury (Fig. 2A),
corroborating the earlier reports [18,19]. To elucidate the role of
HO-1 induction we applied two models i) pharmacological
inhibition of HO-1 using SnPPIX and ii) HO-1 deficient mice.
In both cases decrease in HO-1 activity impaired wound healing.
In mice injected subcutaneously with SnPPIX or in HO-1
deficient individuals, the delay was statistically significant already
on the first day after wounding, while in case of intraperitoneal
injections of SnPPIX it became apparent on the 3rd day. Probably
after s.c. application the inhibitor was instantaneously in contact
with the injured tissues while after i.p. delivery the saturation point
of SnPPIX in the organism was reached later. It should be also
kept in mind that SnPPIX, being a competitive inhibitor of HO-1,
may in the same time induce HO-1 expression. Therefore it
decreases enzymatic activity of HO-1, but usually is unable to
block it completely. We suppose that this is a reason of much
weaker effect of pharmacological than genetic inhibition of HO-1
on wound healing.
Interestingly, the effect of HO-1 deficiency increased with age
and was much stronger in 6-month old than in 3-month old
animals (Fig. 3A,B). Moreover, we did not observe significant
delay in wound closure in younger heterozygous mice, whereas the
effect of decreased level of HO-1 in older heterozygotes was
strong, leading to complete inhibition of reepithelialization and
formation of skin lesions in some individuals. Similar effects of
aging in HO-1 deficient mice have been observed earlier in studies
on endotoxemic stress [28], kidney inflammation [29], fibrosis and
hepatic injury [30]. Disease symptoms typical for HO-1 deficiency,
including anemia, iron-loading, lipid peroxidation, and chronic
inflammation, that were not detectable at 6–9 weeks of age,
became first evident by around 20 weeks [28].
Noteworthy, anemia is known to impair wound healing, as
demonstrated in older people [31] or in sickle cell disease patients
[27]. It is also a very frequent complication of diabetes, occurring
in about 20% of patients, in whom it constitutes a significant
additional burden, accompanied by systemic inflammation [32].
Increasing severity of symptoms in aging mice may suggest that
effect of HO-1 deficiency on wound healing is not only direct, but
may be also indirect, resulting from progressing hemolytic anemia
or augmented injury of tissues caused by continues inflammatory
reaction and oxidative stress.
While HO-1 inhibition impairs healing of excisional wounds,
overexpression of HO-1 may facilitate this process. We demon-
strated that tissue-specific upregulation of HO-1 in keratinocytes is
enough to accelerate wound closure and augment vascularization.
It seems important, as keratinocytes can be relatively easily
isolated from patients and expanded in vitro. Such keratinocyte
preparations are already used in clinic for treatment of burn
injuries [33]. Our study may suggest that pharmacological HO-1
upregulation or gene delivery of HO-1 to the cultured cells could
further improve their therapeutic potential. Indeed, as we have
shown previously, HO-1 upregulates VEGF synthesis and
angiogenic potential of cultured human keratinocytes [34]. The
application of HO-1 by-products can be also considered, as both
CO and biliverdin were demonstrated to upregulate VEGF
production in endothelial cells [13] and keratinocytes [24],
respectively.
Importantly, we found that expression of HO-1 can be reduced
in diabetic animals. We observed impaired induction of HO-1 in
response to hemin in the skin of db/db mice, when compared to
the wild type counterparts. Western-blot analysis suggested also
some delay in induction of HO-1 in wounded skin. Interestingly,
the reduced response to hemin has been already observed in
myocardium of diabetic rats [35].
Data describing effect of diabetes on HO-1 expression are,
however, conflicting. It has been demonstrated, especially in
chemically induced diabetes in alloxan- or streptozotocin-injected
animals, that HO-1 is upregulated in different cell types, soon after
induction of hyperglycemia [36–40]. This was possibly associated
Figure 5. Activity of primary murine keratinocytes isolated
from HO-1+/+ and HO-1Tg newborns and cultured in vitro. A –
Migration of cells measured by time of gap closure in the presence of
hydroxyurea (10 mmol/L). Scratch assay. B – Spontaneous proliferation
of cells cultured for 48 h. BrdU incorporation assay. C – Viability of cells
cultured in hypoxia (1% O2) for 24 h. MTT reduction assay. D –
Concentration of VEGF in media harvested from cell cultures after a
24 h incubation. Each bar represents mean+SD of 3–5 experiments. *
P,0.05, ** P,0.01 in comparison to HO-1+/+.
doi:10.1371/journal.pone.0005803.g005
HO-1 Accelerates Wound Healing
PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5803
with increased oxidative stress, as HO-1 upregulation could be
reduced by antioxidants [37]. However, it has been suggested that
diabetes-induced oxidative stress is, in part, due to pro-oxidant
activity of HO-1, mediated by increased redox-active iron [41].
Induction of HO-1 was also reported in spontaneously diabetic
rats [42] and in type 2 diabetic patients, especially those with
nephropathy or atherosclerosis [43–45].
On the contrary, there are many reports demonstrating
downregulation of HO-1 expression in diabetes. Thus, the
impaired levels of HO-1 were found within the ciliary bodies
[46], cardiac tissue [35] or aortas [47–49] of streptozotocin-
hyperglycemic rats and in the brain of Goto-Kakizaki rats [50].
Reduced basal expression of HO-1 was also demonstrated in type
2 diabetes patients in retinal pigment epithelium [51], leukocytes
[52], and skeletal muscles [53].
Experiments carried out in animals treated with HO-1 inducers
or inhibitors suggest that HO-1 may play a beneficial role in
diabetes, attenuating the hyperglycemia-related complications.
Thus, pharmacological activation of HO-1 in streptozotocin-
injected rats led to protection of endothelial cells [47], restoration
Figure 6. A – Closure of cutaneous wounds in the HO-1+/+ wild type and HO-1Tg mice. Each bar represents mean+SD. N = 10 animals per
group. * P,0.05, ** P,0.01, *** P,0.001 in comparison to HO-1+/+ mice. B – Representative pictures demonstrating CD31 staining of endothelial cells
in the wounded skin (3 days after wounding) in the 3-month old mice of different genotypes. Scale bar = 100 mm. C – Number of vessels in wounded
skin (3 days after wounding, CD31 staining) in the 3-month old mice of different genotypes. Each bar represents analysis of samples from 5–8 animals.
Data are presented as mean+SD. * P,0.05 in comparison to HO-1+/+ animals.
doi:10.1371/journal.pone.0005803.g006
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Figure 7. A – Closure of cutaneous wounds in the wild type (WT) and db/db diabetic C57BL mice. Each bar represents mean+SD; N= 10
animals per group. ** P,0.01, *** P,0.001 in comparison to WT animals. B – Number of vessels in healthy and wounded skin in the WT and db/db
mice. Each bar represents analysis of samples from 10 animals. Data are presented as mean+SD. * P,0.05 in comparison to healthy skin (day 0); #
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of normal rates of endothelial progenitor cell recruitment [49], and
decreased production of proinflammatory cytokines after ischemia
reperfusion stress [35]. This could be associated with higher
concentration of serum bilirubin and reduced production of
reactive oxygen species [47]. Similar finding, namely decreased
oxidant production and oxidative-mediated injury was reported in
patients with high HO-1 expression [44,48].
Our data indicate for the first time that local delivery of HO-1
transgene by means of adenoviral vectors was sufficient to improve
healing of excisional wounds in diabetic db/db mice, despite a low
transduction efficacy. Unfortunately, we were unable to detect a
difference in concentration of HO-1 protein in lysates of injured
tissues between animals treated with therapeutic HO-1 or control
GFP cDNAs on the 3rd day after gene transfer. Possibly the
expression of transgene was masked by induction of endogenous
HO-1, induced by wounding, inflammatory response to adenovi-
ral vectors and by GFP expression [54]. The ELISA assay used for
measuring the HO-1 protein in tissue lysates appears to be not
sensitive enough to detect a subtle difference. We demonstrated,
however, that HO-1 level was sustained in AdHO-1 treated
animals on day 14th, when endogenous HO-1 was already
attenuated, which implies a successful gene delivery. Expression
of GFP in control wounds and presence of rat HO-1 mRNA in
AdHO-1 treated wounds, detected also on 3rd day, confirms that
adenoviral gene transfer was effective. It seems, that even such
local overexpression of HO-1 can still improve wound closure and
vascularization. Thus, a similar strategy could be proposed for
diabetic patients suffering from non-healing ulcers.
There are several possible mechanisms underlying the influence
of HO-1 on healing of wounds, since its products exert
proangiogenic, anti-apoptotic, cytoprotective and anti-inflamma-
tory effects. One potential pathway is an inhibition of production
of inflammatory cytokines. This may facilitate the wound healing
and increase the reepithelialization, as demonstrated in several
reports [55–57]. In our model, however, the effect of HO-1 on
inflammatory response is not so clear. Analysis of blood collected
three days after wounding showed that concentrations of many
cytokines or growth factors are higher in mice of normal level of
HO-1, whereas HO-1 deficiency or inhibition results in decreased
cytokine production. Such relation was observed for sCD40
antigen, IL-2, KC, IL-17, IFNc, and GM-CSF. One can suppose,
that the differences observed do not result from a direct effect of
HO-1 on cytokine expressions, but are rather the consequences of
different rate of wound closure, where at the same time the
progression of healing is delayed in animals of lower HO-1
activity. Experiments carried out in HO-1 overexpressing mice
seem to confirm lack or relatively weak influence of HO-1 on the
cytokine production in response to wounding, as level of cytokines
at the wound site was more dependent on wounding phase that on
HO-1 activity, while production of inflammatory cytokines in
transgenic keratinocytes was similar to control cells (data not
shown).
It has been also postulated that HO-1 is beneficial in wound
healing, due to protection of cells from toxic effects of reactive
oxygen species, which are intensively generated at the site of
injury, especially during first two days, in the inflammatory phase
[18,58]. Such a protective effect of HO-1 was demonstrated in
many models, including ischemia/reperfusion injury [59], ciga-
rette smoke-induced airway mucus hypersecretion [60], nephrop-
athy [61] or corneal inflammation [26].
Significance of reduction of oxidative stress is indicated by
experiments and clinical trials in which antioxidants improved
wound healing, leading to increased epithelial cell proliferation
and augmented angiogenesis [62–64]. Role of HO-1 in wounded
skin may be especially important, as in cutaneous wounds the
expressions of other antioxidative enzymes such as superoxide
dismutase, glutathione peroxidase, glutathione-S-transferase, or
catalase, as well as concentrations of ascorbic acid, vitamin D, and
glutathione were significantly decreased [65].
HO-1 may also directly influence keratinocytes, facilitating their
migration, improving survival in a stressful conditions of oxidative
stress or hypoxia and tending to augment their proliferation.
Cytoprotective and anti-apoptotic effects of HO-1 is very well
documented [24]. Similarly, the important role of HO-1 in
migration has been already shown in endothelial cells [13], and
endothelial progenitors [17]. It seems that pro-migratory effect
HO-1 depends on CO-induced phosphorylation and activation of
vasodilator-activated phosphoprotein (VASP), a cytoskeletal-asso-
ciated protein involved in motility, which is a downstream target
for SDF-1 or IL-8 [17]. Recent study on microvascular endothelial
cells has revealed that CO might regulate VASP phosphorylation
and vascular cell migration also in diabetic conditions [66]. Thus,
it seems that HO-1 dependent increase in migration and/or
survival of keratinocytes and fibroblasts might contribute to
improved wound closure.
One of the crucial processes influencing tissue regeneration is
angiogenesis. Thus, disturbed blood vessel formation, for example
in mice with inhibited VEGF production in epidermal keratino-
cytes leads to delay in wound closure [5,67]. Several studies,
including those performed in diabetic animals, have demonstrated
the importance of neovascularization not only in excisional
wounds [7–9,17,68], but also in burn injuries [69] or hind limb
ischemia [70]. Thus, induction of angiogenesis by VEGF [4] or
basic fibroblast growth factor (bFGF) [71] can be proposed as a
therapeutic strategy improving wound healing. Importantly,
induction of HO-1 in human keratinocytes upregulates their
angiogenic potential and may restore the VEGF production
impaired by high glucose level [33].
HO-1 may augment tissue neovascularization through in-
creased production and/or activity of proangiogenic mediators,
such as VEGF, monocyte chemotactic protein-1 (MCP-1),
transforming growth factor-1 (TGF-b) or SDF-1, and decreased
synthesis of anti-angiogenic agents, like soluble VEGF receptor 1
(sVEGFR1), soluble endoglin (sEng) or IL-10 [11,13,17,24,33].
Hence, HO-1 gene transfer to the rat ischemic muscle [15] or to
pancreatic carcinoma [16] can improve angiogenesis.
As expected, we observed impaired vascularization both in HO-
1 deficient mice and in db/db mice, in which induction of HO-1
upon injury was weaker. Importantly, HO-1 gene transfer, leading
to faster wound closure, resulted also in significantly augmented
neovascularization in diabetic animals. Similarly, overexpression
of HO-1 in keratinocytes in transgenic animals was associated with
increased number of blood vessels in injured tissue. This suggests
that beneficial role of HO-1 in wound healing may result from its
P,0.05 in comparison to WT animals. C – Representative pictures showing blood vessels in healthy and wounded skin of WT and db/db mice.
Immunohistochemical staining for CD31. Scale bar = 100 mm. D – Western blot analysis of HO-1 protein expression in healthy and wounded skin of
the WT and db/db mice. One of 5 similar blots. E – Western blot analysis of HO-1 protein expression in healthy skin of the wild type and db/db mice
24 h after intradermal injection with hemin (10 mg/kg of body weight). One of 2 similar blots. Tubulin was used as a housekeeping gene to control
the protein loading.
doi:10.1371/journal.pone.0005803.g007
HO-1 Accelerates Wound Healing
PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e5803
Figure 8. Expression of GFP and HO-1 transgenes in skin. A – Representative pictures showing the expression of GFP in the wounded skin of
db/db diabetic mice, 3 days after local injection with AdGFP adenoviral vectors (2.36107 IU). Bright field and fluorescence microscopy. Scale
bar = 100 mm. B – Concentration of HO-1 protein in tissue lysates of healthy and wounded skin of db/db mice, measure on the 3rd and 14th days after
AdGFP and AdHO-1 vector delivery. Each bar represent mean+SD for 5–8 animals.# P,0.05 in comparison to healthy skin; * P,0.05 in comparison to
AdGFP injected animals. C – RT-PCR analysis of rat HO-1 mRNA and total (rat/murine) mRNA in wounded skin, measured on the 1st and 3rd days after
AdGFP and AdHO-1 vector delivery. Electrophoresis of RT-PCR products in 2% agarose gel. NC-negative control, HS-healthy skin.
doi:10.1371/journal.pone.0005803.g008
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proangiogenic activity. We confirmed decreased level of VEGF in
the blood of HO-1 deficient animals three days after wounding,
and tendency for reduced VEGF production in the wounded skin.
Additionally, overexpression of HO-1 in keratinocytes was
associated with slight, but statistically significant increase in VEGF
synthesis in hypoxia. Stimulatory effect of HO-1 was also reported
for hypoxia-induced VEGF expression in human keratinocytes
[33]. Interestingly, in mice injected with SnPPIX, we did not
observe decreased expression of VEGF in the blood (Table 1).
Moreover, there was no difference in expression of VEGF in
wounded skin and in number of blood vessels (data not shown).
This may suggest that many effects of SnPPIX are HO-1
independent and that inhibition of wound closure by SnPPIX
and by HO-1 deficiency relies on distinct mechanisms. Similar
observations were reported in studies on effects of pharmacological
or genetic HO-1 inhibition in cancer progression [72].
We found the reduced concentration of soluble CD40 antigen
and IL-17 in HO-1 deficient mice. Both proteins may stimulate
angiogenesis [73,74]. Similar decrease was observed for proangio-
genic IL-2 and KC, the cytokines which can accelerate the wound
Figure 9. Effect of HO-1 transgene delivery on wounds. A – Effect of HO-1 transgene delivery on wound closure in the db/db diabetic mice.
Adenoviral vectors (2.36107 IU in 100 mL of PBS) were injected subcutaneously near the wound immediately after injury. Control animal were
injected with the same amount of AdGFP carriers. Each bar represents mean+SD; N= 5–8 animals per group. * P,0.05 in comparison to control,
AdGFP treated mice. B – representative pictures showing blood vessels in the wounded skin of db/db mice injected with AdHO-1 or AdGFP vectors.
CD31 staining of the skin cross-section. Scale bar = 100 mm. C – Number of vessels in wounded skin in the db/db mice injected with AdHO-1 or
AdGFP, on the 3rd and 14th days after wounding. Analysis of specimens stained for CD31 to visualize endothelial cells. Each bar represents mean+SD
values for 5–8 animals. * P,0.05 in comparison to control, AdGFP injected animals.
doi:10.1371/journal.pone.0005803.g009
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healing process through stimulating the proliferation of dermal
fibroblasts or through augmenting the maturation of granulose
tissue, respectively [75,76]. Finally low activity of HO-1 led to
decreased level of GM-CSF, the proangiogenic growth factor
which facilitates wound contraction and induces keratinocyte
proliferation and migration [77]. One could suggest that reduction
of those mediators might contribute to wound healing impairment
observed in HO-1 deficient mice.
In summary, our study indicates that activation of HO-1
accelerates wound healing in normoglycemic and diabetic mice,
what can be associated with augmented angiogenesis, increased
migratory capacities and improved survival of keratinocytes.
Overexpression of HO-1 by in vivo gene transfer or ex vivo
transduction of keratinocytes may be proposed as a strategy for
improvement of wound healing in diabetic patients.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the Local
Ethical Committee for Animal Research at the Jagiellonian
University.
Reagents
SnPPIX was from Frontier Scientific (Carnforth, UK); Mouse
Cytokine Antibody Array kit from Ray-Biotech (Norcross, GA);
Anti-mouse CD31 and rhodamine-conjugated rat anti-mouse
antibodies from BD Biosciences (Franklin Lakes, NJ); Rabbit anti-
HO-1 antibody from Stressgen (Ann Arbor, MI); goat anti-rabbit-
HRP antibody from CellSignaling Technology (Danvers, MA);
Dispase, trypsin-EDTA, glutamine, sodium pyruvate, nonessential
amino acids, penicillin, streptomycin, b-mercaptoethanol,
DMEM, and FCS from Gibco (Carlsbad, CA); Epidermal
Keratinocyte Medium from CELLnTEC (Bern, Switzerland);
Kit for ASPAT measurement from Biomerieux (Marcy l’Etoile,
France); ELISA for VEGF from R&D (Minneapolis, MN); QIAzol
from Qiagen (Valencia, CA); Turbo DNA Free Kit from Ambion
(Austin, TX); M-MLV and oligo(dT)15 primers from Promega
(Madison, WI); DNAzyme-II DNA polymerase from Finnzymes
(Espoo, Finland); Cell Proliferation Kit from Roche (Basel,
Switzerland); Adeno-X Virus Production Kit, Adeno-X Virus
Purification Kit, and Adeno-X rapid titer ELISA from Clontech
(Mountain View, CA); All other reagents were from Sigma-
Aldrich (St. Louis, MO). All materials were approved for
investigational-use only.
Cell culture
HaCaT cells (immortalised human keratinocytes), kindly
provided by Dr. Robert Fusening (Heidelberg University,
Germany), were grown in DMEM medium, supplemented with
FBS (10%), penicillin (100 U/ml) and streptomycin (10 mg/ml).
Isolation and culture of primary keratinocytes
Skins were excised from 1-5-day old pups, purified of fat,
washed in PBS with penicillin (100 U/ml) and streptomycin
(100 mg/ml), and incubated overnight with dispase (6 U/ml).
Epidermis was removed with forceps, placed in 0.05% trypsin-
EDTA solution for a few minutes, and neutralized using complete
DMEM with 10% FCS. Cell suspension was centrifuged at 200 g
for 5 minutes at room temperature. The isolated keratinocytes
were cultured in serum free CnT-07 PCT Epidermal Keratinocyte
Medium.
Detection of human and rat HO-1 mRNA in the skin
RNA was extracted from homogenized healthy or wounded
skins using QIAzol and purified with Turbo DNA FreeTM kit.
Two micrograms of total RNA was used for reverse transcription
with M-MLV and oligo(dT) primers. PCR was performed with
primers for human HO-1 (F: 59-GGAGGTCATCCCCTACA-
CACC-39; R: 59-CTGGGAGCGGGTGTTGAGTG-39), and
constitutive human EF2 (F: 59-GACATCACCAAGGGTGTG-
CAG-39; R: 59-TCAGCACACTGGCATAGAGGC-39) or with
primers for rat HO-1 (F: 59-AGAGTCCCTCACAGACA-
GAGTTT-39; R: 59-CCTGCAGAGAGAAGGCTACATGA-39),
murine/rat HO-1 (F: 59-CTTTCAGAAGGGYCAGGTGWCC-
39; R: 59-GTGGAGMCGCTTYACRTAGYGC-39) and consti-
tutive murine EF2 (F: 59GACATCACCAAGGGTGTGCAG-39;
R: 59-TCAGCACACTGGCATAGAGGC-39). Real-time PCR
reaction was done in cycles: 95uC for 30 s, 60uC for 60 s, 72uC for
45 s; data were analyzed with DCt method. In regular PCR the
reaction was done in cycles: 95uC for 45 s, 60uC for 30 s, 72uC for
60 s. We did 25 cycles for total (murine/rat) HO-1, and 35 cycles
for rat HO-1.
Cell proliferation assay
Spontaneous cell proliferation was assessed by BrdU incorpo-
ration colorimetric assay performed according to the manufactur-
er’s protocol. Cells (5,000 per well) were seeded in 96-well plate
and assayed 48 h later.
Migration assay
Cells were grown to full confluence and treated with 10 mM
hydroxyurea to block proliferation. A scratch was generated with a
pipette tip. Photographs were taken at different time points, always
from the same place, and analyzed using ImageJ programme
(National Institute of Health, http://rsb.info.nih.gov/ij).
MTT reduction assay
Thiazolyl blue tetrazolium bromide solution was added to the
cells (0.5 mg/ml) for 0.5–1 h. Then, medium was removed and
100 ml of 2-propanol with 5 mM HCl were added to dissolve the
formazan crystals. Optical density was measured at 560 nm.
Preparation of adenoviral vectors
Adenoviral vectors containing rat HO-1 cDNA (Ad-HO1) were
kindly gifted by Dr. Gisa Tiegs (Erlangen, Germany). Control
vectors harboring GFP cDNA (Ad-GFP) were produced using the
Adeno-X system. Both vectors were propagated in 293 cells,
purified using Adeno-X Virus Purification kit, and titrated with
Adeno-X rapid titer ELISA kit.
Animals and wound healing model
Mice were anesthetized with isoflurane, wiped with 70%
ethanol and shaved. Once the skin was exposed, two full-thickness
(including panniculus carnosus) circular wounds (4 mm in
diameter) on each animal were created using disposable biopsy
punch. Each wound was photographed every day and analyzed
using ImageJ software. For biochemical or immunohistochemical
analysis wounded skin, together with a margin of healthy skin, was
excised using 8 mm-diameter biopsy punch.
Injection with SnPPIX. Immediately after wounding, mice
(C57Bl/6, 3-month old) were divided into four groups and injected
daily either intraperitoneally or subcutaneously with SnPPIX
(45 mmol/kg of body weight, dissolved in 0.2 M NaOH), or with a
vehicle (0.2 M NaOH in PBS).
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Adenoviral-mediated HO-1 gene transfer. Mice (db/db,
3-month old) were injured and injected intracutaneously at 3
points near the wound with AdGFP or AdHO-1 (100 ml,
2.36108 IU/ml per wound). Each mouse received the same
vector/vehicle in both wounds to avoid possible effects from
leakage.
HO-1 induction in skin in mice after injection with
hemin. C57BL wild type and C57BL db/db mice were
injected intradermally with hemin (10 mg/kg of body weight).
Animals were sacrificed after 24 hours and HO-1 expression was
determined by immunoblotting.
Protein isolation and western blotting
Skin was homogenized, lysed in 200 ml of ice-cold lysis buffer
(PBS with 1% Triton X-100, 0.1 mg/ml PMSF, 1 mg/ml leupeptin
and 1 mg/ml aprotinin), incubated on ice for 30 minutes, and
centrifuged at 10,000 rpm at 4uC for 10 min. Supernatants were
stored at 280uC. Samples were subjected to SDS-PAGE and
immunoblotting as described earlier [13].
CD31 staining
The wounds were cut into 8 mm slides. Cryosections were dried
and blocked for at least 1 h with 10% goat serum, 0.05% Tween
and 0.1% Triton 6100 in PBS. Either rat anti-mouse CD31 or
isotypic antibodies 1:100 in 106 diluted blocking buffer were
applied for 1.5 h and then sections were washed with PBS.
Secondary antibodies conjugated with rhodamine 1:1000 in PBS
were applied for 0.5 h and the sections were washed with PBS.
Slides were analyzed under the fluorescent microscope. Capillaries
were counted in panniculus carnosus layer, in the direct vicinity of
granulation tissue, at 4006magnification.
Mouse cytokine antibody array
Cytokines in blood serum were analyzed using Ray-Biotech
Mouse Cytokine Antibody Array kit, according to vendor’s
protocol.
Statistical analysis
Statistical analysis was done using Student’s t test or ANOVA
followed by Tukey test. Data are presented as a mean6SD of 3–6
experiments.
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